Successful salvage chemotherapy with amrubicin for invasive thymoma associated with myasthenia gravis

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Anthracycline-based regimens with cisplatin have been commonly used for inoperable and relapsed thymoma. However, little information is available regarding the usefulness of salvage chemotherapy. Here, we describe a case of invasive thymoma associated with myasthenia gravis that showed a marked response to third-line chemotherapy, with single-agent amrubicin, a synthetic anthracycline analog and potent deoxyribonucleic acid topoisomerase II inhibitor. Amrubicin appears to have significant activity against invasive thymoma.

Cite

CITATION STYLE

APA

Fukushima, T., Gomi, D., Kobayashi, T., Sekiguchi, N., Sakamoto, A., Sasaki, S., & Koizumi, T. (2014). Successful salvage chemotherapy with amrubicin for invasive thymoma associated with myasthenia gravis. Japanese Journal of Clinical Oncology, 44(11), 1120–1122. https://doi.org/10.1093/jjco/hyu136

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free